Tigen Pharma Options MSK CAR T-cell therapy

Tigen Pharma, SA obtained an option for a license to commercially develop a product from Memorial Sloan Kettering Cancer Center (MSK), in January 2024.

Tigen is supporting the ongoing Phase 1 clinical trial at MSK for an autologous CD371 CAR T-cell product in relapsed/refractory acute myeloid leukemia (AML) developed at MSK with the support of the Sanders TDI.

Under the terms of the option agreement, the collaboration will be intensified around technical and clinical development to accelerate the program to its next stage of clinical development.

Sanders TDI congratulates MSK on this exciting development and anticipates a future where this molecule provides much-needed treatment for AML patients.